Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and impact of the MIC, growth rate, and resistance gen....

<?php echo get_the_title(); ?>
Neue Suche PDF Herunterladen URSACHENMEDIZIN
Hope WW, Warn PA, Sharp A, Howard S, Kasai M, Louie A, Walsh TJ, Drusano GL, Denning DW (2006)
Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and impact of the MIC, growth rate, and resistance genotype on the antifungal effect
Antimicrob Agents Chemother 50
pp. 3680–3688
Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and impact of the MIC, growth rate, and resistance genotype on the antifungal effect

Candida valida, Stuhl-Isolat, SG-Rand, 200-fache Vergrößerung

Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and impact of the MIC, growth rate, and resistance genotype on the antifungal effect

Candida glabrata, Stuhl-Isolat, SG-Rand, 200-fachen Vergrößerung

Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and impact of the MIC, growth rate, and resistance genotype on the antifungal effect

Geotrichum candidum, Stuhl-Isolat, Reis, 4 Tage, 200-fache Vergrößerung

Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and impact of the MIC, growth rate, and resistance genotype on the antifungal effect

Candida tropicalis, Stuhl-Isolat, Reis, -5 Tage, 400-fache Vergrößerung, Kontrast

Candidose; Flucytosin; Candida albicans

Check-ups auf pathogene Hefen

Check-ups for pathogenic yeasts

Ursachenmedizinische Untersuchung und Behandlung krankmachender Pilzinfektionen.

KONTAKT

Wir beraten Sie gerne über die möglichen Ursachen Ihrer Beschwerden.

Unseren zentralen Normamed-Service in Berlin erreichen Sie unter

+49 30 212 34 36 300 service@normamed.com
Links
Normamed Service

© 2025 Normamed S.A..